Clinical, immunological and genetic features in eleven Algerian patients with major histocompatibility complex class II expression deficiency

Allergy, Asthma and Clinical Immunology

Volumn 8, Issue 1, 2012, Pages

  Djidjik, Réda ^a   Messaoudani, Nesrine ^a   Tahiat, Azzedine ^a   Meddour, Yanis ^b   Chaib, Samia ^b   Atek, Aziz ^a   Khiari, Mohammed E ^a   Benhalla, Nafissa K ^c   Smati, Leila ^c   Bensenouci, Abdelatif ^a   Baghriche, Mourad ^c   Ghaffor, Mohammed ^a  

^a Centre Hospitalier et Universitaire de Beni Messous Algiers   (Algeria)

^b Hopital Central de l'Armee   (Algeria)

^c Service d'Endocrinologie   (Algeria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN; RFXANK PROTEIN; UNCLASSIFIED DRUG;

ABSCESS; ALGERIA; ANTIBIOTIC PROPHYLAXIS; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; DIARRHEA; FAILURE TO THRIVE; FEMALE; GENE DELETION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; INFANT; INTERSTITIAL PNEUMONIA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2 EXPRESSION DEFICIENCY; MALE; MONOCYTE; MUTATIONAL ANALYSIS; PRESCHOOL CHILD; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; SCHOOL CHILD; THRUSH; UROGENITAL TRACT INFECTION;

EID: 84870346611     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-8-14     Document Type: Article

References (35)

1. Chapel H. Classification of primary immunodeficiency diseases by the International Union of Immunological Societies (IUIS) expert committee on primary immunodeficiency 2011. Clin Exp Immunol 2012, 168(1):58-59. 10.1111/j.1365-2249.2012.04561.x, 22385238.
2. Griscelli C, Fischer A, Grospierre B, Durandy A, Bremard C, Charron D, Vilmer E, Virelizier J-L. Clinical and immunological aspects of combined immunodeficiency with defective expression of HLA antigens 1984, Amsterdam: Excerpta Medica.
3. Griscelli C, Lisowska-Grospierre B, Mach B, et al. Combined immunodeficiency with defective expression in MHC class II genes. Immunodeficiencies 1993, 141. Chur, Switzerland: Harwood Academic, Rosen FS, Seligman M.
4. Durand B, Sperisen P, Emery P, et al. RFXAP, a novel subunit of the RFX DNA binding complex, is mutated in MHC class II deficiency. EMBO J 1997, 16:1045-1055. 10.1093/emboj/16.5.1045, 1169704, 9118943.
5. Masternak K, Barras E, Zufferey M, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998, 20:273-277. 10.1038/3081, 9806546.
6. Steimle V, Durand B, Barras E, et al. A novel DNA binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). Genes Dev 1995, 9:1021-1032. 10.1101/gad.9.9.1021, 7744245.
7. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). Cell 1993, 75:135-146.
8. Fondaneche MC, Villard J, Wiszniewski W, et al. Genetic and molecular definition of complementation group D in MHC class II deficiency. Hum Mol Genet 1998, 7:879-885. 10.1093/hmg/7.5.879, 9536093.
9. Hume CR, Lee JS. Congenital immunodeficiency associated with absence of HLA class II antigens on lymphocyte result from distinct mutations in transacting factors. Hum Immunol 1989, 26:288-309. 10.1016/0198-8859(89)90007-4, 2511169.
10. Krawczyk M, Reith W. Regulation of MHC class II expression, a unique regulatory system identified by the study of a primary immunodeficiency disease. J Compilation 2006, 67:183-197.
11. Lisowska-Grospierre B, Fondaneche MC, Rols MP, et al. Two complementation groups accent for most cases of inherited MHC class II deficiency. Hum Mol Genet 1994, 3:953-958. 10.1093/hmg/3.6.953, 7951244.
12. Reith W, Satola S, Sanchez CH, et al. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X. Cell 1988, 53:897-906. 10.1016/S0092-8674(88)90389-3, 3133120.
13. Masternak K, Muhlethaler-Mottet A, Villard J, et al. CIITA is a transcriptional coactivator that is recruited to MHC II promoters by multiple synergistic interactions with an enhanceosome complex. Genes Dev 2000, 14:1156-1166. 316580, 10809673.
14. Steimle V, Siegrist CA, Mottet A, et al. Regulation of MHC class II expression by interferon mediated by the transactivator gene CIITA. Science 1994, 265:106-109. 10.1126/science.8016643, 8016643.
15. Klein C, Lisowska-Grospierre B, Ledeist F, et al. Major histocompatibility complex class II deficiency: clinical manifestations, immunological features and outcome. J Pediatr 1993, 123(6):921-928. 10.1016/S0022-3476(05)80388-9, 8229525.
16. Ouederni M, Vincent QB, Frange P, et al. Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients. Blood 2011, 118(19):5108-5118. 10.1182/blood-2011-05-352716, 21908431.
17. Report of an IUIS Scientific Group Primary immunodeficiency diseases. Clin Exp Immunol 1999, 118(suppl 1):1-28. 1905383, 10540200, Report of an IUIS Scientific Group.
18. Wiszniewski W, Fondaneche MC, Lambert N, et al. Founder effect for a 26-bp deletion in the RFXANK gene in North African major histocompatibility complex class II deficient patients belonging to complementation group B. Immunogenetics 2000, 51:261-267. 10.1007/s002510050619, 10803838.
19. Nagarajan UM, Louis-Plence P, DeSandro A, et al. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. Immunity 1999, 10:153-162. 10.1016/S1074-7613(00)80016-3, 10072068.
20. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003, 112(5):973-980. 10.1016/j.jaci.2003.07.003, 14610491.
21. Griscelli C. Combined immunodeficiency with defective expression in MHC class II genes. Clin Immunol Immunopathol 1991, 61:106-110.
22. Bejaoui M, Barbouche MR, Dellagi K. Les déficits immunitaires primitifs en Tunisie; étude de 152 cas. Arch Pediatr 1997, 4:827-831. 10.1016/S0929-693X(97)88145-6, 9345562.
23. Benallegue M, Kedjif F. Consanguinité et santé publique, étude algérienne. Arch Fr Pédiatr 1984, 41:435-440.
24. Bousfiha AA, Ailal F, Picard C, et al. Epidémiologie et classification des déficits immunitaires primitifs. Rev Mar Mal Enf 2008, 18:5-11.
25. Lamdaouer Bouazzaoui N. Consanguinité et Santé publique au Maroc. Bull Acad Natl Med 1994, 178:1013-1027.
26. Griscelli C, Lisowska-Grospierre B, Le Deist F, et al. Combined immunodeficiency with abnormal expression of MHC class II genes. Clin Immunol Immunopathol 1989, 50:S140-S148. 10.1016/0090-1229(89)90121-9, 2463126.
27. Bejaoui M, Barbouche MR, Mellouli F, et al. Déficit immunitaire primitif par défaut d'expression des antigènes de classe II: neuf observations tunisiennes. Arch Pediatr 1998, 5:1089-1093. 10.1016/S0929-693X(99)80005-0, 9809151.
28. Saleem MA, Arkwright PD, Davies EG, et al. Clinical course of patients with major histocompatibility complex class II deficiency. Arch Dis Child 2000, 83:356-359. 10.1136/adc.83.4.356, 1718526, 10999878.
29. Nekrep N, Geyer M, Jabrane-Ferrat N, Peterlin BM. Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome. Mol Cell Biol 2001, 21:5566-5576. 10.1128/MCB.21.16.5566-5576.2001, 87278, 11463838.
30. Lennon-Dumenil AM, Barbouche MR, Vedrenne J, et al. Uncoordinated HLA-D gene expression in a RFXANK-defective patient with MHC class II deficiency. J Immunol 2001, 166:5681-5687.
31. Nagarajan UM, Peijnenburg A, Gobin SJ, et al. Novel mutations within the RFX-B gene and partial rescue of MHC and related genes through exogenous class II transactivator in RFX-Bdeficient cells. J Immunol 2000, 164:3666-3674.
32. Prod'homme T, Dekel B, Barbieri G, et al. Splicing defect in RFXANK results in a moderate combined immunodeficiency and long-duration clinical course. Immunogenetics 2003, 55:530-539. 10.1007/s00251-003-0609-2, 14574520.
33. Wiszniewski W, Fondaneche MC, Louise-Plence P, et al. Novel mutations in the RFXANK gene: RFX complex containing in vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. Immunogenetics 2003, 54:747-755.
34. Naamane H, El Maataoui O, Ailal F, et al. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. Eur J Pediatr 2010,
35. Wiszniewski W, Fondaneche MC, Le Deist F, et al. Mutation in the class II trans-activator leading to a mild immunodeficiency. J Immunol 2001, 167:1787-1794.